Posts tagged “PPD”

December 1, 2011

Premium Lock PPD shareholders vote decisively to approve $3.9B sale

PPD The Wilmington-based contract research organization is set to be taken over by The Carlyle Group and Hellman & Friedman.

November 30, 2011

Premium Lock It's decision day for PPD shareholders on $3.9B sale

PPD The Wilmington-based contract research organization has scheduled a meeting for shareholders to vote whether to approve the sale to private equity firms The Carlyle Group and Hellman & Friedman. Online and telephone voting closed Tuesday night.

November 4, 2011

Premium Lock Life science awards go to PPD, Novartis, Steve Burrill

Life science Scrips, an international life science media and related services firm based in the U.K., honors PPD with two awards, Novartis with three, and names Burrill its lifetime achievement winner.

Updated November 2, 2011

Premium Lock 'Go shop' is over for PPD; $3.9B deal goes to shareholders

PPD The life sciences services firm says it failed to find any "alternative acquisition" offers during a 30-day period in which it sought a better deal than the one made with Carlyle Group.

October 31, 2011

Premium Lock PPD fails to find a better offer than $3.9B

PPD The Wilmington-based life science services firm entered into an agreement to sell the company to Carlyle and H&F for $3.9 billion on oct. 2 and didn't get a better offer in "go shop" effort.

October 31, 2011

Premium Lock PPD's private equity deal - How the deal got done

PPD There's a slim chance another bidder could eclipse the $33.25 offer that was ultimately reached. The sale agreement includes a "go shop" provision that allows PPD to consider higher bids if submitted within 30 days of the October 2 merger agreement. Morgan Stanley has contacted a total of 22 parties: nine companies and 13 financial entities.

October 12, 2011

Premium Lock Will PPD's new top exec stay onboard after $3.9B sale?

Ray Hill If Ray Hill is on his way out, the CRO has made no such indications. In the proxy statement filed with the SEC, the company includes a letter from PPD founder and Chairman Fred Eshelman distributed to all employees. In the letter, Eshelman said: "Nothing will change in our day-to-day operations as a result of this transaction. Our management team is working closely together to ensure the company remains focused on our current objectives and strategy. We believe the experience and leadership skills of our senior management team, including CEO Ray Hill, and all of our employees will add great value as we navigate through this transition."

October 7, 2011

Premium Lock Pozen shifts gears in seeking drug development partner

Pozen "It really comes down to how we can maximize the asset," Chief Commercial Officer Liz Cermak said in a conference call with analysts. "We're a little company with a limited amount of resources."

Updated October 3, 2011

Premium Lock PPD's founder unlocks stock value with $3.9B deal

Fred Eshelman, the founder and chairman of the Wilmington life sciences services firm, is also its largest individual stock holder with nearly 7 million shares. The announced going private deal on Monday also doesn't mean PPD won't be worth more before a deal is done. Bloomberg says the deal price was higher before the recent market downturn.

Fred Eshelman   Fred Eshelman

Updated October 3, 2011

Premium Lock PPD shares skyrocket 26% on news of $3.9B deal

PPD The Wilmington-based life science services firm has the option to pursue a better deal over the next 30 days. If a deal is consumated, PPD will become a private company owned by The Carlyle Group and Hellman & Friedman.

Updated October 3, 2011

Premium Lock 'Battlefield 3' beta first impressions: Fun with guns

TechWireGamer: The first thing that strikes this player about the game is how fabulously splendid the graphics are. This is one of the most visually attractive games I have ever played, with the Frostbite 2 engine pushing modern graphics to their utmost.

October 3, 2011

Premium Lock Pozen launches search for partner to commercialize potential drug

Pozen The Chapel Hill-based firm has worked with GSK and AstraZeneca on past products. It has retained a consulting firm to find another partner for a compound under clinical trial that could help prevent cardiovascular disease.

Updated September 21, 2011

Premium Lock PPD's hiring of new CEO may mean no sale of company

Ray Hill The Wilmington-based life science services firm reportedly has been mulling opportunities to be acquired by a private equity firm. Ray Hill's hiring may mean a sale isn't imminent, an analyst says.

Updated September 19, 2011

Premium Lock PPD names veteran life sciences exec as new CEO

PPD Stock drops 8.4 percent at the open. Raymond Hill joins the Wilmington-based firm from a consulting firm. He also joins the contract research organization's board.

Updated August 17, 2011

Premium Lock Sale reports sends PPD shares to 52-week high

The life science services firm, which is based in Wilmington and has an operation in the Triangle, has been shopping for a buyer. Carlyle Group could be the winner, Bloomberg news reports.

Fred Eshelman   Fred Eshelman

Updated July 29, 2011

Premium Lock New arthritis drug's sluggish sales perplex Pozen

Arthritis  The Chapel Hill-based pharmaceutical firm to bring in outside consultants to explore why the drug developed in partnership with pharma giant AstraZeneca isn't selling well.

Updated July 27, 2011

Premium Lock PPD wallops Street expectations - Good news for a buyer?

The Wilmington-based life sciences services company, which has an operation in the triangle, reports more than doubling of earnings and 10 percent jump in revenue.

Fred Eshelman   Fred Eshelman

July 18, 2011

Premium Lock PPD to explore 'unlocking value;' rumors send stock surging 10.3%

Fred Eshelman   In a statement issued after a report about the company possibly being sold, Pharmaceutical Product Development says it management will "review" PPD's strategic plan and capital structure.

Updated July 18, 2011

Premium Lock PPD shares soar 17% on sale report; PRA on block, too?

PPD PRA International, which is based in Raleigh, and Pharmaceutical Product Development, which operates out of Wilmington, are looking for buyers, according to The Wall Street Journal.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith